

Vimpat[®] (lacosamide) – First-time generic

- On March 21, 2022, Tris Pharma launched [Indoco Remedies](#), and [Alembic](#), [Amneal](#) and [Glenmark launched](#) AB-rated generic versions of UCB's [Vimpat \(lacosamide\)](#) tablets.
 - In addition, on March 17, 2022, FDA granted approval to AB-rated generic versions of Vimpat to [Hetero](#), [MSN Laboratories](#), [ScieGen](#) and [Sun Pharmaceuticals](#). These manufacturers may launch generic Vimpat at any time.
- Vimpat is approved for the treatment of partial-onset seizures in patients 1 month of age and older, and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Vimpat is also available as a brand oral solution and injection that carry the same indications as the tablets.
- According to IQVIA, Vimpat tablets had annual sales of \$1.7 billion as of January 2022.